Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate
antimalarial active against drug-resistant P. falciparum infection, and to determine the
effect of a standard fatty meal on the absorption of the drug from the gut and its blood
levels.